NCT06014034

Brief Summary

Purpose of research:to explore a reasonable programmed withdrawal process of noninvasive ventilation and thereby reduce the duration of noninvasive mechanical ventilation in patients with acute exacerbations of chronic obstructive pulmonary disease.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 12, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 9, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 28, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

January 22, 2025

Status Verified

November 1, 2024

Enrollment Period

2.6 years

First QC Date

August 9, 2023

Last Update Submit

January 19, 2025

Conditions

Keywords

noninvasive mechanical ventilation

Outcome Measures

Primary Outcomes (1)

  • Complete evacuation time of non-invasive ventilation

    from the start of the patient to the absence of noninvasive ventilation or return to the level of normal ventilation time for patients with non-invasive ventilation on a home non-invasive ventilator before acute exacerbation

    At the end of non-invasive ventilation,through study completion, an average of 11 days

Secondary Outcomes (3)

  • Time in the ICU

    At the end of therapy in ICU,through study completion, an average of 14 days

  • length of stay

    At the end of therapy in hospital, through study completion, an average of 20 days

  • Failure rate of non-invasive ventilation

    At the end of therapy in hospital, an average of 20 days

Study Arms (2)

Study group

EXPERIMENTAL

Programmed Weaning From Noninvasive Mechanical Ventilation

Other: Programmed Weaning From Noninvasive Mechanical Ventilation

Control group

NO INTERVENTION

this is the traditional withdrawal unit (the attending physician will decide the NIV regimen according to the condition).

Interventions

Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.

Study group

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • It is defined that in patients with acute exacerbation of chronic obstructive pulmonary disease, the arterial blood gas analysis was decompensation of respiratory acidosis, and the pH value was 7.20-7.35
  • Non-invasive mechanical ventilation was performed and it was well tolerated

You may not qualify if:

  • younger than 40 years old
  • pregnancy
  • Human immunodeficiency virus (HIV) antibody was positive
  • Hemodynamic instability
  • Mechanical ventilation for endotracheal intubation and cardiopulmonary resuscitation were disagreed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hospita

Beijing, Beijing Municipality, 100191, China

RECRUITING

Study Officials

  • Qingtao Zhou

    Peking University Third Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Qingtao Zhou

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2023

First Posted

August 28, 2023

Study Start

May 12, 2023

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

January 22, 2025

Record last verified: 2024-11

Locations